This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Welcome to the latest news from The Oxford Science Park, where you can keep up to date with developments across our community. From company milestones and scientific breakthroughs to investment news, partnerships, events and Park announcements, discover how our occupiers are advancing innovation and shaping the future. 

Media enquiries: comms@oxfordsp.com

 

 

Moa awarded Defra funding to accelerate blackgrass control solutions for English farmers

Moa Technology has been awarded over £900,000 in non-dilutive funding through the Defra Farming Innovation Investor Partnership (FIIP) programme delivered in partnership with Innovate UK, to advance the development of exciting new solutions for the control of blackgrass. Blackgrass costs UK agriculture hundreds of millions of pounds annually through reduced crop yields and increased input costs, which could rise to £1 billion a year in losses... Read more

Welcoming UK Agri-Tech Centre to The Oxford Science Park

The Oxford Science Park is pleased to welcome the UK Agri-Tech Centre, which joined the Park earlier this year. The UK Agri-Tech Centre supports agri-tech companies to prove, build and scale technologies that address the challenges facing agriculture, horticulture and aquaculture. By connecting businesses with farmers, growers, researchers, investors and industry partners, it helps promising technologies move from development and testing... Read more

Scancell receives UK approval to begin Phase 3 melanoma trial

Scancell, a clinical-stage immuno-oncology company based at The Oxford Science Park, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to begin a Phase 3 clinical trial of its lead cancer treatment, iSCIB1+, in patients with advanced melanoma. The trial is an important step towards potentially bringing iSCIB1+ to patients. It is expected to involve 550 people with advanced melanoma across around 90... Read more

Moa Technology announces £22.2m Series C funding

Moa Technology has announced a £22.2 million Series C financing round, co-led by Oxford Science Enterprises and Supernova Invest. This new investment reflects the strength of Moa’s IP and the progress it has made to become the innovation partner of choice for the crop protection industry.   In the last 24 months, Moa has formed R&D collaborations with four leading companies - Nufarm, Gowan, Certis Belchim and Corteva Agriscience – to develop... Read more

Oxford Vacmedix announce successful Phase 1 trial results for cancer

Oxford Vacmedix , a biotech company developing novel immunotherapies to treat cancer, has announced the successful completion of the Phase 1 trial of OVM-200. The primary endpoint for safety has been met as well as the secondary endpoints for immune response and dose selection. In addition, there are early observations of clinical efficacy in NSCLC and in prostate cancer. This Phase 1 clinical trial of OVM-200 is a multicentre, open‑label,... Read more